- Home
- GERN vs CIFR Comparison
GERN vs CIFR Comparison
Compare GERN & CIFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GERN | CIFR |
|---|---|---|
| Founded | 1990 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 9.0B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GERN | CIFR |
|---|---|---|
| Price | $1.31 | $19.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $2.17 | ★ $24.91 |
| AVG Volume (30 Days) | 8.8M | ★ 30.3M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,065,000.00 | ★ $223,942,000.00 |
| Revenue This Year | $26.91 | $12.29 |
| Revenue Next Year | $43.75 | $240.53 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 48.04 |
| 52 Week Low | $1.04 | $11.01 |
| 52 Week High | $2.01 | $30.14 |
Technical Indicators
Market Signals| Indicator | GERN | CIFR |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 55.68 |
| Support Level | $1.24 | $16.77 |
| Resistance Level | $1.32 | $19.81 |
| Average True Range (ATR) | 0.07 | 1.33 |
| MACD | -0.02 | 0.45 |
| Stochastic Oscillator | 10.00 | 88.32 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
About CIFR Cipher Mining Inc.
Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.